argenx SE reported $1.58B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AstraZeneca USD 31.27B 286M Sep/2026
Genmab DKK 1.14B 38M Jun/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
GRIFOLS EUR 2.3B 59M Sep/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Lakefront Biotherapeutics EUR 70.32M 30.1M Jun/2026
Qiagen NV USD 581.45M 102.34M Jun/2026
UCB EUR 4.4B 470M Dec/2025